Lisa Andersson

Ms. Lisa Andersson

orcid

Research Focus & Metrics

Academic Career Length

36Years (1991-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2020 in Cells
Verified
Journal Article
Open access
PDF file
EJEmma Jonasson
Emma Jonasson
LALisa Andersson
Lisa Andersson
SDSoheila Dolatabadi
Soheila Dolatabadi
SGSalim Ghannoum
Salim Ghannoum
PÅPierre Åman
Pierre Åman
ASAnders Ståhlberg
Anders Ståhlberg
Single-cell analysis enables detailed molecular characterization of cells in relation to cell type, genotype, cell state, temporal variations, and microenvironment. These studies often include the analysis of individual genes and networks of genes. The total amount of RNA also varies between cells due to important factors, such as cell type, cell size, and cell cycle state. However, there is a lack of simple and sensitive methods to quantify the total amount of RNA, especially mRNA. Here, we developed a method to quantify total mRNA levels in single cells based on global reverse transcription followed by quantitative PCR. Standard curve analyses of diluted RNA and sorted cells showed a wide dynamic range, high reproducibility, and excellent sensitivity. Single-cell analysis of three sarcoma cell lines and human fibroblasts revealed cell type variations, a lognormal distribution of total mRNA levels, and up to an eight-fold difference in total mRNA levels among the cells. The approach can easily be combined with targeted or global gene expression profiling, providing new means to study cell heterogeneity at an individual gene level and at a global level. This method can be used to investigate the biological importance of variations in the total amount of mRNA in healthy as well as pathological conditions.

5 April 2011 in Mammalian Genome
Verified
Journal Article
Open access
PDF file
LALisa Andersson
Lisa Andersson
KLKatarina Lyberg
Katarina Lyberg
GCGus Cothran
Gus Cothran
DRDavid T. Ramsey
David T. Ramsey
RJRytis Juras
Rytis Juras
Gabriella LindgrenGabriella Lindgren
Gabriella Lindgren
The syndrome Multiple Congenital Ocular Anomalies (MCOA) is the collective name ascribed to heritable congenital eye defects in horses. Individuals homozygous for the disease allele (MCOA phenotype) have a wide range of eye anomalies, while heterozygous horses (Cyst phenotype) predominantly have cysts that originate from the temporal ciliary body, iris, and/or peripheral retina. MCOA syndrome is highly prevalent in the Rocky Mountain Horse but the disease is not limited to this breed. Affected horses most often have a Silver coat color; however, a pleiotropic link between these phenotypes is yet to be proven. Locating and possibly isolating these traits would provide invaluable knowledge to scientists and breeders. This would favor maintenance of a desirable coat color while addressing the health concerns of the affected breeds, and would also provide insight into the genetic basis of the disease. Identical-by-descent mapping was used to narrow the previous 4.6-Mb region to a 264-kb interval for the MCOA locus. One haplotype common to four breeds showed complete association to the disease (Cyst phenotype, n = 246; MCOA phenotype, n = 83). Candidate genes from the interval, SMARCC2 and IKZF4, were screened for polymorphisms and genotyped, and segregation analysis allowed the MCOA syndrome region to be shortened to 208 kb. This interval also harbors PMEL17, the gene causative for Silver coat color. However, by shortening the MCOA locus by a factor of 20, 176 other genes have been unlinked from the disease and only 15 genes remain.

1 December 1991 in Animal Genetics
Verified
Journal Article
Closed access
PDF file
SSS. Sigurdardóttir
S. Sigurdardóttir
PMP. Mariani
P. Mariani
Martien GroenenMartien Groenen
Martien Groenen
JVJ. VAN
J. VAN
DPDER Poel
DER Poel
LALisa Andersson
Lisa Andersson

10 February 2020 in Policy Studies
Verified
Journal Article
Open access
LALisa Andersson
Lisa Andersson
Over the past decades, Europe has seen increasing interest in and pressure to coordinate social policy. Studies on the coordination of social policies have found that institutional settings affect coordination patterns when comparing different welfare state ideal-types. Adding to this body of research, this paper compares two countries with diverging authority to regulate social policy areas; Sweden representing a unitary decentralized state and the UK representing a regionalized state. With labour market programs for youth serving as a case, the purpose of this paper is to compare the development of inter- and intra-policy coordination over a period of 10 years, analysing the impact of regulatory authority. Policy documents which set the regulatory frame of the programs are analysed from the perspectives of instruments, and territorial levels of regulatory authority and how these connect to coordination patterns. The results show that levels of discretion and processes of decentralization and fragmentation of regulatory authority impact on coordination patterns, where inter- and intra-coordination develops under different circumstances.

24 April 2009 in Animal Blood Groups and Biochemical Genetics
Verified
Journal Article
Closed access
PDF file
RJR. Juneja
R. Juneja
LALisa Andersson
Lisa Andersson
KSK. Sandberg
K. Sandberg
BGB. Gahne
B. Gahne
SAS. Adalsteinsson
S. Adalsteinsson
EGE. Gunnarsson
E. Gunnarsson

7 March 2022 in Biomedicines
Verified
Journal Article
Open access
PDF file
CVChristoffer Vannas
Christoffer Vannas
LALisa Andersson
Lisa Andersson
SDSoheila Dolatabadi
Soheila Dolatabadi
PRParmida Ranji
Parmida Ranji
MLMalin Lindén
Malin Lindén
PÅPierre Åman
Pierre Åman
The therapeutic options for patients with relapsed or metastatic myxoid liposarcoma (MLS) remain scarce and there is currently no targeted therapy available. Inhibition of the HSP90 family of chaperones has been suggested as a possible therapeutic option for patients with MLS. However, the clinical effect of different HSP90 inhibitors vary considerably and no comparative study in MLS has been performed. Here, we evaluated the effects of the HSP90 inhibitors 17-DMAG, AUY922 and STA-9090 on MLS cell lines and in an MLS patient-derived xenograft (PDX) model. Albeit all drugs inhibited in vitro growth of MLS cell lines, the in vivo responses were discrepant. Whereas 17-DMAG inhibited tumor growth, AUY922 surprisingly led to increased tumor growth and a more aggressive morphological phenotype. In vitro, 17-DMAG and STA-9090 reduced the activity of the MAPK and PI3K/AKT signaling pathways, whereas AUY922 led to a compensatory upregulation of downstream ERK. Furthermore, all three tested HSP90 inhibitors displayed a synergistic combination effect with trabectidin, but not with doxorubicin. In conclusion, our results indicate that different HSP90 inhibitors, albeit having the same target, can vary significantly in downstream effects and treatment outcomes. These results should be considered before proceeding into clinical trials against MLS or other malignancies.